Immunodiagnostic Systems Holdings plc revised revenue guidance for the fourth quarter ended March 31, 2016. The company announced that the royalties payable to IDS for the quarter ended March 31, 2016 would be lower than they had originally indicated. As a result, while total royalty revenue is in line with the prior year, the company has seen an unexpected reduction in royalty revenue for the last quarter of the year ended March 31, 2016. Therefore reported revenue for the year will be closer to £38 million than the £39 million which was previously announced. Additionally the company now expects this royalty revenue stream to reduce significantly going forwards.